Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, discusses data from the Phase II trial (NCT03542266) investigating oral azacitidine, a DNA demethylating agent, and CHOP in patients with relapsed/refractory peripheral T-Cell Lymphoma (PTCL). 20 patients who received six cycles of CHOP and oral azacytidine priming were evaluated, with the primary endpoint being complete response (CR). Addition of azacytidine significantly improved CR and stem cell transplant was successfully performed in half of patients. The novel regimen will be additionally assessed in the A051902 study (NCT04803201). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.